美诺华(603538.SH)子公司阿托伐他汀钙原料药通过CDE技术审评

Core Viewpoint - The company Menova (603538.SH) announced that its subsidiary Xuancheng Menova Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of atorvastatin calcium raw material [1] Group 1 - Xuancheng Menova's atorvastatin calcium raw material has passed the CDE technical review, confirming that it meets national drug review technical standards [1] - The approval allows the raw material to be sold in the domestic market, which will enrich the subsidiary's product line [1] - This development is expected to help expand the company's business scope and enhance its integrated production advantages in the raw material and formulation sectors [1]